Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer

Li,Ming; Zhang,Xiao‑Lei; Deng,Fang; Qian,Li‑Ting; Meng,Shui‑Ping; Shan,Wu‑Lin; Wang,Bao‑Long

doi:10.3892/ol.2016.5087

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer

Authors:
- Ming Li
- Xiao‑Lei Zhang
- Fang Deng
- Li‑Ting Qian
- Shui‑Ping Meng
- Wu‑Lin Shan
- Bao‑Long Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, P.R. China, Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China, Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China
Published online on: September 5, 2016 https://doi.org/10.3892/ol.2016.5087
Pages: 3330-3336
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human papilloma virus (HPV) infection has previously been reported to be associated with TP53 and TP16 expression in Japanese and Taiwanese patients with lung cancer, but data for advanced non‑small cell lung cancer (NSCLC) patients is limited. The present study examined the association between HPV infection and TP53 and TP16 expression in Chinese patients with advanced NSCLC. HPV DNA was detected in 20 out of 83 (24%) lung tumors, and was observed more frequently in non‑smokers, patients with lymph node metastasis, and patients with poorly differentiated tumors (P=0.048, P=0.044 and P=0.024, respectively). Thirteen (65%) out of 20 HPV‑infected tumors were positive for TP53 expression while eight (40%) were positive for TP16 expression. Multivariate analysis revealed that poor differentiation alone (OR=0.163) was an independent predictive factor of HPV infection in NSCLC. TP16‑positive patients had a significantly longer survival time when compared with TP16‑negative patients (P<0.001, log‑rank test), a trend a not observed for TP53. Our results suggest that TP53 and TP16 protein expression is not associated with the expression of HPV DNA, but that TP16 expression may be an independent prognostic factor of long survival in advanced NSCLC.

View Figures

View References

1	Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
2	Murray CJ and Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global burden of disease study. Lancet. 349:1498–1504. 1997. View Article : Google Scholar : PubMed/NCBI
3	Lam WK, White NW and Chan-Yeung MM: Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis. 8:1045–1057. 2004.PubMed/NCBI
4	Rezazadeh A, Laber DA, Ghim SJ, Jenson AB and Kloecker G: The role of human papilloma virus in lung cancer: A review of the evidence. Am J Med Sci. 338:64–67. 2009. View Article : Google Scholar : PubMed/NCBI
5	Castle PE, Cuzick J, Stoler MH, Wright TC Jr, Reid JL, Dockter J, Giachetti C and Getman D: Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: Results from the CLEAR HPV study. Am J Clin Pathol. 143:160–167. 2015. View Article : Google Scholar : PubMed/NCBI
6	Slama J, Sehnal B, Dusek L, Zima T and Cibula D: Impact of risk factors on prevalance of anal HPV infection in women with simultaneous cervical lesion. Neoplasma. 62:308–314. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zur Hausen H: Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
8	Park MS, Chang YS, Shin JH, Kim DJ, Chung KY, Shin DH, Moon JW, Kang SM, Hahn CH, Kim YS, et al: The prevalence of human papillomavirus infection in Korean non-small cell lung cancer patients. Yonsei Med J. 48:69–77. 2007. View Article : Google Scholar : PubMed/NCBI
9	Isa SI, Kurahara Y, Yamamoto S, Tamiya A, Omachi N, Asami K, Okishio K, Utsumi T, Ito N, Yoon HE, et al: Molecular analysis of human papillomavirus in never-smokers with non-small cell lung cancer. Oncol Lett. 9:927–929. 2015.PubMed/NCBI
10	Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, et al: HPV-associated lung cancers: An international pooled analysis. Carcinogenesis. 35:1267–1275. 2014. View Article : Google Scholar : PubMed/NCBI
11	Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, Su JM and Lee H: The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 61:2799–2803. 2001.PubMed/NCBI
12	Srinivasan M, Taioli E and Ragin CC: Human papillomavirus type 16 and 18 in primary lung cancers-a meta-analysis. Carcinogenesis. 30:1722–1728. 2009. View Article : Google Scholar : PubMed/NCBI
13	Koshiol J, Rotunno M, Gillison ML, Van Doorn LJ, Chaturvedi AK, Tarantini L, Song H, Quint WG, Struijk L, Goldstein AM, et al: Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst. 103:501–507. 2001. View Article : Google Scholar
14	Proctor I, Stoeber K and Williams GH: Biomarkers in bladder cancer. Histopathology. 57:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
15	Helt AM, Funk JO and Galloway DA: Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol. 76:10559–10568. 2002. View Article : Google Scholar : PubMed/NCBI
16	Murao K, Yoshioka R and Kubo Y: Human papillomavirus infection in Bowen disease: Negative p53 expression, not p16INK 4a overexpression, is correlated with human papillomavirus- associated Bowen disease. J Dermatol. 41:878–884. 2014. View Article : Google Scholar : PubMed/NCBI
17	Vainshtein J, McHugh JB, Spector ME, Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT, Bradford CR, et al: Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. Head Neck. 37:8–11. 2015. View Article : Google Scholar : PubMed/NCBI
18	Maniakas A, Moubayed SP, Ayad T, Guertin L, Nguyen-Tan PF, Gologan O, Soulieres D and Christopoulos A: North-American survey on HPV-DNA and p16 testing for head and neck squamous cell carcinoma. Oral Oncol. 50:942–946. 2014. View Article : Google Scholar : PubMed/NCBI
19	Umbreit C, Aderhold C, Faber A, Sauter A, Hofheinz RD, Stern-Straeter J, Hoermann K and Schultz JD: Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Oncol Rep. 32:668–676. 2014.PubMed/NCBI
20	Zhang EY and Tang XD: Human papillomavirus type 16/18 oncoproteins: Potential therapeutic targets in non-smoking associated lung cancer. Asian Pac J Cancer Prev. 13:5363–5369. 2012. View Article : Google Scholar : PubMed/NCBI
21	Suzuki Y, Oonishi T, Kudo T and Doi H: LKB1, TP16, EGFR and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. Drug Discov Ther. 6:24–30. 2012.PubMed/NCBI
22	Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Francova HS, Doubek M, et al: Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol. 29:2703–2708. 2011. View Article : Google Scholar : PubMed/NCBI
23	Vainshtein J, McHugh JB, Spector ME, Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT, Bradford CR, et al: Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. Head Neck. 37:8–11. 2015. View Article : Google Scholar : PubMed/NCBI
24	Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM and Peters S: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
25	Syrjanen KJ: Condylomatous changes in neoplastic bronchial epithelium. Respiration. 38:299–304. 1979. View Article : Google Scholar : PubMed/NCBI
26	Hasegawa Y, Ando M, Kubo A, Isa S, Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M and Kawaguchi T: Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature. Lung Cancer. 83:8–13. 2014. View Article : Google Scholar : PubMed/NCBI
27	Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et al: Evidence for acausal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
28	Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prey. 14:467–475. 2005. View Article : Google Scholar
29	Subramanian J and Govindan R: Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol. 9:676–682. 2008. View Article : Google Scholar : PubMed/NCBI
30	Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al: Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
31	Gatta LB, Balzarini P, Tironi P, Berenzi A, Benetti A, Angiero F, Grigolato P and Dessy E: Human papillomavirus DNA and p16 gene in squamous cell lung carcinoma. Anticancer Res. 32:3085–3089. 2012.PubMed/NCBI
32	Su CY, Chang YC, Chan YC, Lin TC, Huang MS, Yang CJ and Hsiao M: MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. Eur J Surg Oncol. 40:1143–1150. 2014. View Article : Google Scholar : PubMed/NCBI